27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Coronavirus vaccine play Inovio Pharmaceuticals Inc (NASDAQ:INO) is not an outright buy at this point in time, according to an analyst at Piper Sandler.
The Inovio Analyst
Christopher Raymond maintained a Neutral rating on Inovio shares with an $8 price target.
The Inovio Thesis
The 12-month overall survival data Inovio presented for its DNA cancer vaccine INO-5401 in glioblastoma multiforme — a deadly form of brain cancer — at the ASCO made the benefit less clear, Raymond said in a Monday note. (See his track record here.)
The vaccine is being studied in a Phase 2 single-arm study in newly diagnosed GBM patients following gross total resection and in combo with radiotherapy, temozolomide and Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) Libtayo, he said.
"While the data have demonstrated that a subset of patients had a T cell response to treatment, there is still uncertainty over INO-5401's individual therapeutic benefit."
Longer-term and randomized data for the vaccine would help Piper Sandler feel more confident in the program, Raymond said.
An overall survival update due later this year is a key catalyst for the program, the analyst said. Given the uncertainty, he said INO-5401 remains an unmodeled opportunity at this point.
Piper Sandler sees several upcoming catalysts for Inovio, including first-in-human data from INO-4800 due later this month and an update on potential funding for the program to support further development.
"However, given the ongoing volatility surrounding this name over COVID-19 efforts, we prefer to watch this story play out from the sidelines," Raymond said.
INO Price Action
At last check, Inovio shares were down 5.85% at $13.99.
Related Links:
The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!